Hach Rose Schirripa & Cheverie LLP Announces $55 Million Settlement in Antitrust Class Action Against Celgene
July 26 2019 - 1:24PM
Hach Rose Schirripa & Cheverie LLP, a nationally recognized
plaintiffs’ law firm dedicated to handling complex litigation,
announced earlier this week that it has reached a $55 million
settlement with Celgene Corporation (NASDAQ: CELG) in a
long-running class action, In re Thalomid and Revlimid
Antitrust Litigation. The settlement is one of the largest
pharmaceutical settlements on behalf of end payors (consumers,
insurers, union health and welfare funds, municipalities, and
others) in an antitrust case in the last decade.
Founding partner, Frank Schirripa, said, “We are
very pleased to have achieved such a sizable settlement on behalf
of cancer patients and our Taft-Hartley Health and Welfare clients
who have shouldered the cost of these life-saving medications.”
Hach Rose Schirripa & Cheverie filed this
class action suit in 2014, alleging that Celgene had monopolized
the market for two drugs, Thalomid and Revlimid, which are
primarily used to treat multiple myeloma, a cancer that forms in
the blood. Specifically, the plaintiffs alleged that Celgene
kept generic versions of these two drugs off the market, in
violation of state and federal antitrust laws. Throughout the
litigation, the end payor plaintiffs asserted that prices for the
two drugs were higher than they would have been in a competitive
market.
The parties agreed to resolve the case following
the close of discovery and during the pendency of the plaintiffs’
motion to certify the class. Any person or entity that paid
for some or all of the purchase price of Thalomid or Revlimid in
California, the District of Columbia, Florida, Kansas, Maine,
Massachusetts, Michigan, Nebraska, New York, North Carolina,
Oregon, Pennsylvania, Rhode Island, or Tennessee, for use by
themselves, their families, or their members, employees, insureds,
participants, or beneficiaries, will be invited to file a claim to
participate in the settlement.
Hach Rose Schirripa & Cheverie attorneys
working on this case include Frank Schirripa, Daniel Rehns, Seth
Pavsner and Kathryn Hettler. The other lead counsel in the
case were Hausfeld LLP and Block & Leviton LLP.
For further information or to arrange
interviews please contact:
Frank
Schirripafschirripa@hrsclaw.com212-213-8311
About Hach Rose Schirripa &
Cheverie
Hach Rose Schirripa & Cheverie LLP
specializes in the fields of antitrust, securities, corporate
governance and consumer protection litigation. Over the past
twenty years, the firm’s attorneys have established themselves as
leading representatives of investor and consumer rights in these
areas. The firms’ attorneys have successfully litigated
complex class actions in both state and federal courts through the
United States and are committed to protecting consumers’ rights,
investors’ assets and victims of corporate wrongdoing. For
more information about the firm, please visit www.hrsclaw.com.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2023 to Sep 2024